Cargando…

Long-term impact of adult WHO grade II or III gliomas on health-related quality of life: A systematic review

BACKGROUND: Glioma diagnosis can be devastating and result in a range of symptoms. Relatively little is known about the long-term health-related quality of life (HRQOL) challenges faced by these patients. Establishing the impact of diagnosis on HRQOL could help positively tailor clinical decision ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frances, Sé Maria, Velikova, Galina, Klein, Martin, Short, Susan C, Murray, Louise, Wright, Judy M, Boele, Florien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789291/ https://www.ncbi.nlm.nih.gov/pubmed/35087674 http://dx.doi.org/10.1093/nop/npab062

Ejemplares similares

Bevacizumab in recurrent WHO grades II–III glioma
por: Annakib, Soufyan, et al.
Publicado: (2023)

Long-term unmet supportive care needs of teenage and young adult (TYA) childhood brain tumour survivors and their caregivers: a cross-sectional survey
por: Nicklin, Emma, et al.
Publicado: (2021)

Multiparametric MRI-based differentiation of WHO grade II/III glioma and WHO grade IV glioblastoma
por: Wiestler, Benedikt, et al.
Publicado: (2016)

T2 mapping of molecular subtypes of WHO grade II/III gliomas
por: Kern, Maike, et al.
Publicado: (2020)

Psychiatric symptoms in glioma patients: from diagnosis to management
por: Boele, Florien W, et al.
Publicado: (2015)

The long-term caregiver burden in World Health Organization grade I and II meningioma: It is not just the patient
por: Zamanipoor Najafabadi, Amir H, et al.
Publicado: (2020)

Healthcare utilization and productivity loss in glioma patients and family caregivers: the impact of treatable psychological symptoms
por: Boele, Florien W., et al.
Publicado: (2020)

Integrative analysis of TP73 profile prognostic significance in WHO grade II/III glioma
por: Chen, Yanming, et al.
Publicado: (2021)

Basement-Membrane-Related Gene Signature Predicts Prognosis in WHO Grade II/III Gliomas
por: Zhang, Zhaogang, et al.
Publicado: (2022)

Communication in the context of glioblastoma treatment: A qualitative study of what matters most to patients, caregivers and health care professionals
por: Boele, Florien W, et al.
Publicado: (2023)

Importance of evaluating health-related quality of life issues in survivors of WHO grade II or III gliomas
por: Dirven, Linda
Publicado: (2022)

Unmet support needs in teenage and young adult childhood brain tumour survivors and their caregivers: “it’s all the aftermath, and then you’re forgotten about”
por: Nicklin, Emma, et al.
Publicado: (2021)

Current therapeutic approaches to diffuse grade II and III gliomas
por: Picca, Alberto, et al.
Publicado: (2018)

Radiation Treatment for WHO Grade II and III Meningiomas
por: Walcott, Brian P., et al.
Publicado: (2013)

SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II–III Diffuse Gliomas
por: Zhang, Yu-An, et al.
Publicado: (2016)

Treatment Recommendations for Adult Patients with Diffuse Gliomas of Grades II and III According to the New WHO Classification in 2016
por: SASAKI, Hikaru, et al.
Publicado: (2017)

Diffusion tensor image features predict IDH genotype in newly diagnosed WHO grade II/III gliomas
por: Eichinger, Paul, et al.
Publicado: (2017)

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy
por: Steidl, Eike, et al.
Publicado: (2021)

Radiological differences between subtypes of WHO 2016 grade II–III gliomas: a systematic review and meta-analysis
por: van Lent, Djuno I, et al.
Publicado: (2020)

The Value of H2BC12 for Predicting Poor Survival Outcomes in Patients With WHO Grade II and III Gliomas
por: Zhou, Jie, et al.
Publicado: (2022)

Prognosis Individualized: Survival predictions for WHO grade II and III gliomas with a machine learning-based web application
por: Karabacak, Mert, et al.
Publicado: (2023)

Patient and caregiver return to work after a primary brain tumor
por: Nicklin, Emma, et al.
Publicado: (2023)

Long-term wellbeing and neurocognitive functioning of diffuse low-grade glioma patients and their caregivers: A longitudinal study spanning two decades
por: Boele, Florien W, et al.
Publicado: (2022)

PROX1 is a predictor of survival for gliomas WHO grade II
por: Elsir, T, et al.
Publicado: (2011)

EVA1C Is a Potential Prognostic Biomarker and Correlated With Immune Infiltration Levels in WHO Grade II/III Glioma
por: Hu, Zhicheng, et al.
Publicado: (2021)

A Molecular Predictor Reassesses Classification of Human Grade II/III Gliomas
por: Rème, Thierry, et al.
Publicado: (2013)

Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas
por: Watson, Juliana, et al.
Publicado: (2020)

Internet-based guided self-help for glioma patients with depressive symptoms: design of a randomized controlled trial
por: Boele, Florien W, et al.
Publicado: (2014)

Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients
por: Dirven, Linda, et al.
Publicado: (2021)

Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma
por: Choi, Jinhyun, et al.
Publicado: (2020)

The Clinical Value of PET with Amino Acid Tracers for Gliomas WHO Grade II
por: Smits, Anja, et al.
Publicado: (2011)

A Probabilistic Atlas of Diffuse WHO Grade II Glioma Locations in the Brain
por: Parisot, Sarah, et al.
Publicado: (2016)

Extent and prognostic value of MGMT promotor methylation in glioma WHO grade II
por: Karschnia, Philipp, et al.
Publicado: (2020)

Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy
por: Park, Chul-Kee, et al.
Publicado: (2009)

TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas
por: Zhang, Zhen-Yu, et al.
Publicado: (2015)

Development and Validation of an Immune-Related Gene Pairs Signature in Grade II/III Glioma
por: Zhang, Xu, et al.
Publicado: (2021)

Functions of RNF Family in the Tumor Microenvironment and Drugs Prediction in Grade II/III Gliomas
por: Zhang, Jingwei, et al.
Publicado: (2022)

The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01
por: Kim, Young Zoon, et al.
Publicado: (2019)

The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study
por: Corell, Alba, et al.
Publicado: (2020)

Attitudes and preferences toward monitoring symptoms, distress, and quality of life in glioma patients and their informal caregivers
por: Boele, Florien W., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_u3petmir82kmbiotmb5h5epmg7